Population
Over 300 mutants derived from two strains of poliovirus type 3 and 59 monoclonal antibodies to poliovirus…
Design
Preclinical
Authors
Loading...
Identifies dominant poliovirus neutralizing epitope; leaves open whether VP1-based peptides elicit protective immunity in vivo.
Identification of the principal antigenic site of poliovirus type 3 provides a basis for developing synthetic oligopeptide vaccines.
Minor et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: